^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LD013

    i
    Other names: LD013, mesothelin-specific chimeric antigen receptor T cell, LD 013, LD-013
    Associations

    News

    Trials
    Company:
    Nanjing Blue Shield Biotech
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer (clinicaltrials.gov)
    P=N/A, N=3, Completed, Weijia Fang, MD | Recruiting --> Completed | Trial completion date: Feb 2026 --> Feb 2023 | Trial primary completion date: Feb 2026 --> Feb 2023
    Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    MSLN (Mesothelin)
    |
    LD013
    over2years
    Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer (clinicaltrials.gov)
    P=N/A, N=9, Recruiting, Weijia Fang, MD
    New trial • CAR T-Cell Therapy
    |
    MSLN (Mesothelin)
    |
    LD013